Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322270 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
A Phase 3 study of Thrombosis and Venous Thrombosis, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 18
- Study locations
NCT00322270: Completed Phase 3 study of Thrombosis and Venous Thrombosis, sponsored by ARCA Biopharma.
NCT00322270 is a Phase 3 study of Thrombosis and Venous Thrombosis that has completed, run by ARCA Biopharma. The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322270, a Phase 3 study of Thrombosis and Venous Thrombosis, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18
- Study locations
Study Summary
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.
Conditions Studied
Interventions
- DRUG Alfimeprase
Study Locations (18)
Florida
- Bethesda Research Center - Boynton Beach
- Pasco Hernando Oncology Associates - Brooksville
- Mercy Hospital - Miami
- Pasco Hernando Oncology Associate - New Port Richey
Illinois
- Medical and Surgical Specialists - Galesburg
- Cancer Center at Blessing Hospital - Quincy
Michigan
- Kalamazoo Hematology and Oncology - Kalamazoo
- Sparrow Cancer Center - Lansing
Missouri
- Comprehensive Cancer Care Clinic - Jefferson City
- The Center for Cancer Care and Research - St Louis
Ohio
- Gabrail Cancer Center - Canton
- Hematology/Oncology Consultants, Inc. - Columbus
Arizona
- Desert Oasis Cancer Center - Casa Grande
California
- Cancer Research & Prevention Center - Soquel
New Jersey
- UMDNJ-Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00322270 record still lists
NCT00322270 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00322270 lists 18 locations in 11 states (Florida, Illinois, Michigan).
Frequently Asked Questions
What is clinical trial NCT00322270 about?
NCT00322270 is a clinical study titled "Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters". To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.
What is the current status of trial NCT00322270?
This trial is currently completed. It is a Phase 3 study. The study started on 2006-01.
What conditions does trial NCT00322270 study?
This clinical trial studies the following conditions: Thrombosis, Venous Thrombosis, Catheter Occlusion.
What interventions are being tested in trial NCT00322270?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00322270?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00322270 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
COMPLETED · Phase 3
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia